Big Pharma's Quiet Purge Keeps Rolling Through Summer

• 114 roles, effective between June and November
• 60 more roles, effective between July and November
• 76 roles, effective August 21

That's 250 positions at a single campus this year. And it doesn't include the 427 U.S. commercial jobs Novartis cut in 2025, mostly from cardiology sales teams bracing for the loss of patent protection on Entresto, its blockbuster heart failure drug.

The company's explanation sounds almost algorithmic at this point: build a "leaner and simpler" organization. Novartis originally announced plans to eliminate about 8,000 jobs worldwide back in 2022, alongside a cost-savings target it later raised to $1.5 billion. Every few months, another slice of that goal lands on someone's desk in New Jersey.

But just like AbbVie, Novartis isn't only cutting. It's building a new radiopharmaceutical manufacturing site in Denton, Texas, projected to create up to 175 jobs. The company sees radioligand therapy (using targeted radiation to destroy cancer cells) as a major growth engine. Old jobs out, new jobs in; different skills, different cities.

This Isn't a Crisis. It's a Renovation.

If you zoom out, AbbVie and Novartis look less like companies in trouble and more like companies remodeling while the restaurant stays open. Revenues at both firms remain strong. AbbVie's immunology franchise (Skyrizi, Rinvoq) is growing fast enough to offset Humira's decline. Novartis posted solid numbers even as it shed headcount.

So why the layoffs? Because big pharma's economic logic is shifting beneath everyone's feet.

The old model was a sprawling empire: dozens of therapeutic areas, massive sales forces, R&D sites scattered across continents. The new model looks more like a sniper than a shotgun. Fewer bets, bigger stakes, and ruthless capital allocation. Patent cliffs on drugs like Humira, Entresto, Eliquis, and Opdivo are forcing the entire industry to rethink where every dollar goes.

Analysts at EY project that industry-wide layoff rates will stay below 5% of total headcount in 2026, which sounds mild until you remember how many people work in pharma. Across the 17 largest companies, more than 22,000 roles were cut in 2025 alone, a 16% jump from the prior year. The pace may slow in 2026, but the direction hasn't changed.

Who's Hiring, Who's Firing

The restructuring wave isn't limited to AbbVie and Novartis. Novo Nordisk, despite riding the obesity drug boom, cut roughly 9,000 positions globally in late 2025. Merck launched a $3 billion cost-cutting program that includes significant job cuts.

The common thread? Every one of these companies is simultaneously investing heavily somewhere else. Pfizer is doubling down on oncology through its Seagen acquisition. Novo Nordisk keeps expanding GLP-1 manufacturing. AbbVie is building those neuroscience plants.

It's like watching an airline retire its older fleet while ordering new planes. The total number of seats might not change much, but where they fly (and who's in the cockpit) looks completely different.

What This Means for the People in the Middle

For the 85 people in Irvine and the 250 in East Hanover, the macro narrative is cold comfort. These are real jobs at real desks, and a WARN notice doesn't care about your company's growth strategy.

The skills market is shifting fast. Growth roles are clustering in oncology, radiopharma, obesity and metabolic disease, AI and digital health, and complex biologics manufacturing. Meanwhile, positions in legacy small-molecule sales, duplicated regional offices, and broad early-stage discovery are thinning out. Geography matters too: Boston, the Bay Area, Basel, and a few specialized manufacturing hubs are consolidating their grip as pharma's power centers.

Big pharma isn't disappearing. It's just becoming a different animal. The question for everyone who works in the industry, or invests in it, or depends on its medicines: can these companies actually execute the pivot, or are they just cutting their way to a press release?

The layoffs will keep coming. The real story is what gets built in their place.

$290M Says Your Migraine Drugs Aren't Good Enough

A Paragon Biosciences spinout just raised $290 million to go after migraine prevention with a totally different approach. The bet: current drugs leave half of patients undertreated, and a protein called PACAP could be the missing piece.